# SeaStar Medical Holding Corp

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/SeaStar Medical Holding Corp).

## Overview

SeaStar Medical Holding Corp is a U.S.-based medical device company focused on therapies that treat acute and chronic kidney injury through selective cytopheretic devices. Its commercial product, QUELIMMUNE, is used in pediatric patients, while the company also develops an adult SCD program and next-generation device candidates.

## Products & services

• QUELIMMUNE pediatric selective cytopheretic device
• Adult selective cytopheretic device (SCD) program
• Next-generation SCD development
• Clinical development and regulatory support services
• Potential license and collaboration arrangements

- **Commercial medical devices** (60%) — Commercialized QUELIMMUNE devices sold for pediatric use in hospital settings.
- **Clinical-stage device development** (30%) — Adult SCD and next-generation SCD programs under clinical and regulatory development.
- **Grants and collaboration revenue** (10%) — Government grants and potential partner payments that support research and development.

- QUELIMMUNE pediatric selective cytopheretic device
- Adult selective cytopheretic device (SCD) program
- Next-generation SCD development
- Clinical development and regulatory support services
- Potential license and collaboration arrangements

## Customers

SeaStar Medical sells primarily to pediatric hospital customers that use QUELIMMUNE in clinical care settings. Its development pipeline is aimed at hospitals and clinicians treating adult patients with serious kidney injury, with future commercialization dependent on regulatory approval and adoption by medical centers.

- **Pediatric hospital customers** (primary) — Hospitals and pediatric care centers buying QUELIMMUNE for treated pediatric patients.
- **Clinical trial and research partners** (secondary) — Sites and institutions supporting adult SCD studies and regulatory development.
- **Government and grant providers** (secondary) — Public and other grant sources funding research, development, and operations.
- **Potential collaboration partners** (emerging) — Companies or institutions that may provide license, collaboration, or strategic payments.

- Pediatric hospitals purchasing QUELIMMUNE for acute care use
- Hospital clinicians treating children with kidney injury
- Future adult-care hospitals if the adult SCD is approved
- Government grant providers supporting R&D activity
- Potential collaborators or license partners

## Geography

SeaStar Medical is headquartered in the United States and its reported commercial activity is centered there. The company’s customer base, clinical development work, and regulatory interactions are also U.S.-based, so its business is tied closely to FDA approval pathways and U.S. hospital adoption.

- United States is the core operating and commercial market
- FDA approval and HDE status are central to U.S. commercialization
- Hospital sales are currently concentrated in U.S. pediatric sites
- Clinical development is managed through U.S.-based trial activity
- No country-level revenue split was disclosed in the excerpts

## Strategy

The company’s near-term strategy is to expand QUELIMMUNE adoption in pediatric hospitals and build a repeatable commercial base. In parallel, it is advancing the adult SCD program through pivotal clinical development and seeking additional capital, collaborations, and grants to support the pipeline.

- **Commercialize QUELIMMUNE in pediatric hospitals** (short-term) — Commercial sales are the first scalable product revenue source.
- **Advance adult SCD regulatory development** (medium-term) — Adult approval would materially expand the market beyond pediatrics.
- **Secure external funding and partnerships** (short-term) — Development and commercialization require ongoing capital support.

- Expand QUELIMMUNE sales into pediatric hospital accounts
- Advance adult SCD through pivotal clinical trial work
- Develop next-generation SCD technology
- Use grants, equity, debt, and collaborations to fund operations
- Pursue regulatory approvals to broaden the addressable market

## Risks

SeaStar Medical faces substantial financing and going-concern risk because it is still building commercial revenue while funding clinical development. Its business also depends on regulatory outcomes, hospital adoption, and successful execution of clinical trials, all of which can delay or prevent future product sales.

- **Going concern and financing dependence** [critical] — The company states it needs additional capital to fund operations and may need restructuring if financing is unavailable.
- **Regulatory approval risk** [high] — Adult SCD commercialization depends on successful clinical development and FDA approval.
- **Commercial rollout risk** [high] — QUELIMMUNE sales depend on hospital adoption and can fluctuate quarter to quarter.
- **Clinical development risk** [high] — Preclinical and pivotal trial programs are costly and may fail to demonstrate efficacy or safety.

- Going-concern risk if additional financing is unavailable
- Regulatory risk tied to adult SCD approval timing and outcome
- Commercial adoption risk as QUELIMMUNE is introduced to hospitals
- Clinical trial execution risk for the adult program
- Revenue volatility from a small customer base and early commercialization

## Accounting

Revenue recognition is still early-stage and depends on point-in-time product sales of QUELIMMUNE, with prior revenue largely coming from grants. Investors should also watch quarterly volatility, stock-based compensation, and estimates tied to clinical development, financing instruments, and going-concern disclosures, since these can materially affect reported results.

- **Revenue recognition for QUELIMMUNE sales** — Affects reported revenue timing and quarterly comparability
- **Grant revenue recognition** — Can create non-product revenue that is less repeatable
- **Stock-based compensation** — Raises operating expenses and affects loss metrics
- **Going-concern and liquidity estimates** — Influences financial statement presentation and risk disclosure

- Product revenue is early and may fluctuate quarter to quarter
- Grant revenue has historically been a major source of reported revenue
- Stock-based compensation affects R&D and operating expense lines
- Financing instruments and warrants affect equity and cash flow reporting
- Going-concern and liquidity disclosures rely on management estimates

---

*Last updated: 2026-04-29T04:57:46.591229+00:00*